[Click eStock] "CGBio Medtech Accelerates Performance Turnaround with Full-Scale Launch of New Businesses"

On January 6, Leading Investment & Securities predicted that CGBio Medtech will enter a growth phase following a performance turnaround, driven by the full-scale launch of new businesses such as dental implants and ECM skin boosters. The company is now beginning to see tangible results from its diversified business portfolio, expanding beyond its existing orthopedic medical device business.

Han Jeyoon, a researcher at Leading Investment & Securities, stated, "CGBio Medtech began with the manufacturing and sales of orthopedic correction devices and has since expanded into various businesses through mergers and acquisitions. The company is focusing its efforts on securing new growth engines, such as the dental implant business and the ECM skin booster ODM business."

CGBio Medtech entered the dental implant market through the acquisitions of GDS, Allabutment, and Dental Ocean. The company also expanded into the electric energy sector with the acquisition of DM Power in 2017, and into the electric vehicle charger market with the acquisition of Infinity Works in 2021. Market attention is now focused on the dental implant and aesthetic/regenerative medical device sectors, which are expected to accelerate starting in 2026.

The dental implant business is emerging as a key growth pillar for CGBio Medtech. Han noted, "The dental implant business, a new growth driver for the company, is expected to gain momentum starting in 2026. Beginning with the launch of 'Urudent' (utilizing Daewoong Pharmaceutical's Urusa IP) in the first quarter of this year, the company plans to pursue global CDMO opportunities in the future." To this end, production capacity is currently being expanded, and it is estimated that by the first quarter of 2026, the company will have the capability to produce 600,000 units annually.

The characteristics of the dental implant market are also seen as a positive factor. Han explained, "Since the dental implant market has reached a certain level of maturity, cost reduction has become a key issue. Therefore, demand for CDMO services is expected to be sufficient." If the company succeeds in entering the CDMO business after establishing a reference through its own brand 'Urudent,' this business could become a powerful growth engine for CGBio Medtech.

Another growth pillar is the ECM skin booster ODM business. CGBio, the parent company of CGBio Medtech, plans to launch 'CGBio Hyaloinject Fine (ECM Skin Booster)'-an aesthetic version of its joint soft tissue regeneration injectable 'CGBio Hyaloinject'-in the first quarter of this year. CGBio Medtech plans to begin the ODM business for this product around the third quarter of this year.

Han commented, "ECM skin boosters have been highly valued in the market, as evidenced by the successful entries of Hans Biomed and L&C Bio. If CGBio Medtech enters this market, a valuation rerating is expected based on the company's high growth potential."

In terms of performance, a clear improvement trend is also expected. After turning a profit in 2025, CGBio Medtech is forecast to achieve sales of 66.7 billion won in 2026, a 41% increase year-on-year, and an operating profit of 8.4 billion won, up 147%. Han emphasized, "The full-scale launch of the dental implant and CDMO businesses, as well as the skin booster ODM business, are the main reasons for the strong 2026 outlook. This will mark the point at which growth accelerates following the turnaround."